TUDCA vs Milk Thistle: Which Is Better for Liver?

TUDCA is the trendy newcomer in liver supplements; milk thistle is the decades-old herbal standard with hundreds of trials behind it. Forums ask TUDCA vs milk thistle — which is better for liver? — but the frame is misleading: TUDCA is a bile acid acting on bile flow and cellular stress, while milk thistle's silymarin is an antioxidant acting on liver cell membranes. This guide compares mechanisms, trial evidence, doses, safety, and which fits your goal.

About TUDCA

TUDCA (tauroursodeoxycholic acid) is a water-soluble bile acid — the taurine-conjugated form of UDCA (ursodeoxycholic acid). That family connection matters: UDCA is an approved prescription drug for primary biliary cholangitis (PBC), so the bile-acid mechanism has genuine clinical validation. TUDCA itself is sold as a supplement, not a drug.

Its mechanisms are distinct from any herbal liver remedy: reducing endoplasmic reticulum (ER) stress — a 2006 Science paper (Ozcan et al., PMID 16931765; DOI 10.1126/science.1128294) showed TUDCA acting as a "chemical chaperone" in obese/diabetic mice — animal-model evidence, not human trials; promoting bile flow and displacing hydrophobic bile acids — the core mechanism of the UDCA drug family; and protecting liver cells from bile-acid-triggered damage, demonstrated so far mainly in preclinical models (e.g., Song et al. 2023 in a cholestatic mouse model).

What the human trials show: The key TUDCA trial is a small 1996 dose-response study in 24 patients with primary biliary cholangitis (then called primary biliary cirrhosis), using 500–1,500 mg/day for six months; liver enzymes fell significantly with all three doses and diarrhea was the only side effect (Crosignani et al., Dig Dis Sci 1996). TUDCA has also been explored in neurological research — the CENTAUR phase 2 trial of the TUDCA/sodium phenylbutyrate combination (AMX0035) in ALS slowed functional decline over 24 weeks, though the drug was withdrawn in 2024 after a confirmatory phase 3 showed no effect. Its direct human evidence base for general liver support is small — far smaller than milk thistle's. Much supplement marketing extrapolates from UDCA's drug record and animal work, not large TUDCA trials.

About Milk Thistle

Milk thistle (Silybum marianum) is one of the most studied herbal liver remedies in the world. Its active fraction is silymarin — flavonolignans (silibinin/silybin, silychristin, silydianin) from the seeds, typically standardized to 70–80% silymarin.

Its mechanisms (largely from preclinical work, reviewed in Abenavoli et al. 2018): antioxidant activity in liver tissue, hepatocyte membrane stabilization that may reduce toxin uptake in cell models, and proposed support for glutathione, the liver's master antioxidant — the magnitude of these effects in humans is not well established.

What the human trials show: Dozens of trials in non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and drug- or toxin-induced liver injury — with a balanced verdict. One NAFLD RCT (Solhi et al. 2014, n=50) reported ALT falling from 103.1 to 41.4 and AST from 53.7 to 29.1 IU/mL after two months on 140 mg/day silymarin (p<0.001 vs placebo). But the NIDDK's LiverTox database (updated 2020) judges controlled trials in NAFLD and chronic hepatitis C as showing "little or no evidence of benefit" on disease activity, and NCCIH calls the overall liver-disease trial evidence "conflicting or too limited" for firm conclusions. Notably, intravenous silibinin (Legalon SIL) is approved in Europe for amanita (death-cap) mushroom poisoning (LiverTox). The same database notes milk thistle "has not been implicated in causing liver injury" and that oral silymarin is well tolerated even at high daily doses. Caveat: silymarin has poor oral bioavailability (Abenavoli et al. 2018) — part of why trials use high doses, and why phospholipid (phytosome) formulations were developed; one human pharmacokinetic study found a silybin–phosphatidylcholine complex (silipide) achieved ~4.6× the bioavailability of standard silymarin (Barzaghi et al. 1990).

Head-to-Head Comparison

Dosage Guide

Trial-based regimens, not prescriptions. Bile acids are potent — start low with TUDCA.

Form notes: Supplement quality varies in general — products with third-party testing are a reasonable screen (general consumer guidance, not a trial claim). For milk thistle, choose extracts standardized to 70–80% silymarin; phytosome forms showed ~4.6× higher silybin bioavailability than standard silymarin in a human pharmacokinetic study (Barzaghi et al. 1990), at higher cost.

Timing: TUDCA is commonly taken with food as a practical measure to reduce GI upset — not established in trials. Milk thistle is typically taken with meals, divided into 2–3 doses.

Safety & Interactions

TUDCA — potent but less studied in humans. The most reported side effect is diarrhea — the only side effect noted in the Crosignani PBC trial (1996); GI effects are commonly described as dose-dependent, which is why the guide above starts low. Any effect on absorption of fat-soluble drugs is theoretical, not documented. Long-term human safety data as a supplement is limited; most confidence comes from UDCA's prescription record — a related but different compound. People with bile-duct obstruction should not use bile acids without medical supervision — complete biliary obstruction is an outright contraindication for the related drug ursodiol (package insert).

Milk thistle — among the best-tolerated liver remedies studied. Trials consistently report good tolerability; main complaints are mild GI upset or headache (LiverTox; NCCIH). Standard cautions: possible allergy in people sensitive to the Asteraceae (daisy/ragweed) family (WebMD/NCCIH), and theoretical effects on drug-metabolizing enzymes — human studies suggest these are of low clinical significance at standard doses (Gillessen et al. 2020); anyone on narrow-therapeutic-index drugs should still check with a pharmacist.

Cautious with either: anyone with diagnosed liver disease (supplements are adjuncts, never replacements for hepatology care), bile-duct obstruction (TUDCA especially), pregnancy/breastfeeding (insufficient data for both), or multiple prescriptions.

Which Should You Choose?

• Fatty liver (NAFLD) or general liver support → Milk thistle: far deeper human trial record, inexpensive, excellent tolerability.
• Sluggish bile flow or cholestatic patterns → TUDCA: the only one acting directly on bile-acid physiology.
• Alcohol- or toxin-related liver concerns → Milk thistle: its best-studied territory.
• Tight budget or long-term daily use → Milk thistle: a fraction of TUDCA's cost with a longer safety record.

Short version: milk thistle is the evidence-backed generalist; TUDCA is the bile-flow specialist with a thinner human record.

Can You Take Them Together?

No human trials of the TUDCA + milk thistle combination were found in a PubMed search. Mechanistically they don't conflict — bile-acid action vs antioxidant action — so the combination is biologically plausible and some practitioners stack them. But "plausible" is not "proven," and TUDCA's dose-dependent GI effects still apply. Introduce them one at a time to attribute any GI symptoms correctly, and stack only under clinician guidance with diagnosed liver disease.

📢 Disclaimer: This information is for educational purposes only and is not medical advice. Always consult a qualified healthcare professional before starting any new supplement. Sources are linked for verification.

Explore the Full Remedy Database

Browse 500+ organic alternatives for health, wellness, and natural living.